melanoma

Rare nasal melanoma achieved complete response after switching to nivolumab-relatlimab when first-line immunotherapy failed.

A 70-year-old male with sinonasal mucosal melanoma progressed on nivolumab-ipilimumab (unresectable). After switching to nivolumab-relatlimab plus site-directed radiation, he achieved complete response after 8 cycles. Treatment interruption for suspected immune toxicity led to eventual progression.…

Rare nasal melanoma achieved complete response after switching to nivolumab-relatlimab when first-line immunotherapy failed.

Key Findings

Sinonasal mucosal melanoma progressed on nivolumab-ipilimumab and became unresectable
Complete response achieved with nivolumab-relatlimab plus radiation after 8 cycles
Treatment interruption for immune toxicity led to eventual progression
Nivolumab-relatlimab (anti-PD-1 + anti-LAG-3) may be active in post-ipilimumab mucosal melanoma

Implications

Nivolumab-relatlimab is a potential option for mucosal melanoma after standard combination immunotherapy failure. Treatment continuity is critical.

Caveats

Single case report; abstract-only. Very limited generalizability. Broader evidence base needed before recommendations.

Source: Cancer reports (Hoboken, N.J.) — 2026-04-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Rare nasal melanoma achieved complete response after switching to nivolumab-relatlimab when first-line immunotherapy failed.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database